APA (7th ed.) Citation

P, C., J, v. T., AM, F., S, R., A, G., E, T., . . . M, H. (2024). Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial. American journal of hematology, 99(6), 1192. https://doi.org/10.1002/ajh.27304

Chicago Style (17th ed.) Citation

P, Cramer, et al. "Bendamustine, Followed by Obinutuzumab and Idelalisib in Chronic Lymphocytic Leukemia (CLL2-BCG): Final Analysis of a Multicenter, Open-label Phase-II-trial." American Journal of Hematology 99, no. 6 (2024): 1192. https://doi.org/10.1002/ajh.27304.

MLA (9th ed.) Citation

P, Cramer, et al. "Bendamustine, Followed by Obinutuzumab and Idelalisib in Chronic Lymphocytic Leukemia (CLL2-BCG): Final Analysis of a Multicenter, Open-label Phase-II-trial." American Journal of Hematology, vol. 99, no. 6, 2024, p. 1192, https://doi.org/10.1002/ajh.27304.